Hoersholm; February 18, 2016 – Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announces that 45,000 warrants have been issued to key persons, employees, executive board and board of directors.

The board of directors in Medical Prognosis Institute A/S today resolved to issue 45,000 warrants to key persons, employees, executive board and members of the board.

The chairman of the board and the two independent board members receives a total of 10,536 warrants and the executive board receives 2,775 warrants. 

All warrants are issued pursuant to the board of directors’ authorization in article 6.1 in the articles of association.

Each warrant entitles the warrant holder to subscribe for 1 share of nominally DKK 1 in Medical Prognosis Institute A/S; and the board of directors has at the same time resolved to increase the company’s share capital accordingly.

The exercise price for the warrants is DKK 10.62 per warrant.

The warrants vest with 1/36 per month starting 1 July 2016. Unexercised warrants lapse automatically 1 July 2021.

The board of director’s decision will be included in article 6.1 and appendix 4 of the company’s articles of association.

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.

For further information, please contact
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD
e-mail: [email protected]
Phone: +45 21 60 89 22

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark